Dr. Sarit Assouline CML Chronic Myeloid Leukemia
Assistant Professor
Jewish General Hospital
Department of Oncology
Gerald Bronfman Centre
Montreal, Canada
More information about Dr. Assouline at Mc Gill University, Faculty of Médicine
Trials Involving Sarit Assouline
Publications Authored By Sarit Assouline
Leukemia: articles by Sarit E. Assouline - Expertscape
Jewish General Hospital
Department of Oncology
Gerald Bronfman Centre
Montreal, Canada
More information about Dr. Assouline at Mc Gill University, Faculty of Médicine
Trials Involving Sarit Assouline
Publications Authored By Sarit Assouline
Leukemia: articles by Sarit E. Assouline - Expertscape
ARTICLES
Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study
January 10, 2019, Haematologica
Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response
October 2017, PubMed
A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia
September 15, 2016, PubMed
Unexpected Success of Watch and Wait Strategy in a Ponatinib-Intolerant Patient With Chronic Myeloid Leukemia
2016, Journal of Oncology Practice
Major discovery on the mechanism of drug resistance in leukemia and other cancers
May 28, 2014, Institute for Research in Immunology and Cancer (IRIC) – Montreal University
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated with Imatinib
2011, Journal of the National Cancer Institute (JNCI) - Medscape
Monitoring response and resistance to treatment in chronic myeloid leukemia
April 2011, Current Oncology
Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib
February 2008, Haematologica
Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study
January 10, 2019, Haematologica
Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response
October 2017, PubMed
A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia
September 15, 2016, PubMed
Unexpected Success of Watch and Wait Strategy in a Ponatinib-Intolerant Patient With Chronic Myeloid Leukemia
2016, Journal of Oncology Practice
Major discovery on the mechanism of drug resistance in leukemia and other cancers
May 28, 2014, Institute for Research in Immunology and Cancer (IRIC) – Montreal University
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated with Imatinib
2011, Journal of the National Cancer Institute (JNCI) - Medscape
Monitoring response and resistance to treatment in chronic myeloid leukemia
April 2011, Current Oncology
Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib
February 2008, Haematologica